MD Anderson: What's your take on the Novo Nordisk deal?
The EV/EBITDA is around 11.7x, which seems attractive compared to historical highs.
True, but the PEG ratio is 2.55. Isn't growth already priced in? What about Eli Lilly?
Competition is a risk, but the TAM for obesity is expanding rapidly...
Fair point. Now, calculate the implied Equity Value if we assume a 12x multiple.